Press release
Waldenstrom Macroglobulinemia Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | AbbVie, Cellectar Biosciences, TG Therapeutics, Eli Lilly and Company, Celgene Corp., AstraZeneca, ADC Therapeutics S.A., Amge
To Know in detail about the Waldenstrom Macroglobulinemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Waldenstrom Macroglobulinemia Market Forecast
https://www.delveinsight.com/sample-request/waldenstrom-macroglobulinemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key facts of the Waldenstrom Macroglobulinemia Market Report:
• The Waldenstrom Macroglobulinemia market size was valued approximately USD 130 million in 2020 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
• In 2020, the estimated overall incident population of Waldenstrom macroglobulinemia (WM) in the 7MM was above 3,000.
• Spain had the fewest Waldenstrom Macroglobulinemia incident cases (around 150 instances) among the 7MM in 2020
• With more than 1,000 occurrences in 2020, MYD88 has the highest incidence of any gene mutation in the US
• A number of cutting-edge and novel therapies with various mechanisms of action, including BTK, proteasome inhibitors (PI), BCL-2 inhibitors, PI3K-delta, and CK1-epsilon inhibitors, are among the interesting and novel treatments for Waldenstrom Macroglobulinemia that are developing
• A US SEER monitoring study on WM found that the median age at diagnosis was 73 years old and that the incidence in the US was 0.3 per 100,000 people
• In the age category of
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Waldenstrom Macroglobulinemia Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | AbbVie, Cellectar Biosciences, TG Therapeutics, Eli Lilly and Company, Celgene Corp., AstraZeneca, ADC Therapeutics S.A., Amge here
News-ID: 3294344 • Views: …
More Releases from DelveInsight Business Research
Global Tumor Ablation Market to reach USD 4,595.68 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The global Tumor Ablations (EHR) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases that require continuous monitoring, data management, and coordinated long-term care. This demand has fueled the need for integrated healthcare systems capable of connecting patient information across multiple departments and care settings. To support this trend, governments worldwide are introducing initiatives, funding, mandates, and regulatory frameworks to promote EHR…
Global Spinal Implants Market to reach USD 21,899.24 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing prevalence of spinal disorders, especially among the aging population, has substantially driven the demand for corrective surgical procedures. At the same time, the rise in sports-related and trauma-induced spinal injuries is boosting the need for advanced implantable solutions. Additionally, there is a growing preference for non-fusion and motion-preserving devices that maintain spinal mobility and improve patient outcomes, particularly among younger and more active individuals.…
Global Vascular Stents Market to reach USD 18,277.68 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing global incidence of cancer is boosting the demand for effective treatment options such as tumor ablation. Minimally invasive procedures are becoming more popular due to their shorter recovery periods, reduced risks, and cost-effectiveness compared to conventional surgery. At the same time, technological advancements in tumor ablation devices-such as improvements in radiofrequency, microwave, and cryoablation technologies-have enhanced precision, safety, and effectiveness, making these procedures increasingly…
Global Vascular Grafts Market to reach USD 3,153.39 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The increasing prevalence of cardiovascular disorders, along with risk factors like hypertension, diabetes, and obesity, is fueling the demand for surgical interventions, thereby supporting the growth of the vascular graft market. Moreover, greater awareness and the expansion of cardiovascular screening programs are enabling earlier diagnosis and timely treatment, further driving the need for vascular grafts.
DelveInsight's "Vascular Grafts Market Insights, Competitive Landscape and Market Forecast-2032" report provides…
More Releases for Waldenstrom
United States Waldenstrom Macroglobulinemia Market Size, Share, Trends - Exclusi …
"Waldenstrom Macroglobulinemia market is estimated to reach at a high CAGR during the forecast period 2024-2031." As per DataM intelligence research report
Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/waldenstrom-macroglobulinemia-market?sp
United States: Recent Industry Developments
✅ In July 2025, Cellectar Biosciences announced the US FDA granted Breakthrough Therapy Designation for iopofosine I 131 in Waldenstrom macroglobulinemia. This designation accelerates the development and review of this promising targeted radiopharmaceutical therapy.…
Waldenstrom Macroglobulinemia Market Positioned for Accelerated Development Thro …
DelveInsight's "Waldenstrom Macroglobulinemia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Waldenstrom Macroglobulinemia, historical and forecasted epidemiology as well as the Waldenstrom Macroglobulinemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Waldenstrom Macroglobulinemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Waldenstrom Macroglobulinemia Market Forecast
https://www.delveinsight.com/sample-request/waldenstrom-macroglobulinemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Waldenstrom Macroglobulinemia Market to Reach US$ 229.1 Million by 2033
Market Overview:
The waldenstrom macroglobulinemia market reached a value of US$ 146.0 Million in 2022 and expects to reach US$ 229.1 Million by 2033, exhibiting a growth rate (CAGR) of 4.17% during 2023-2033.
According to the IMARC Group, the waldenström macroglobulinemia market exhibited a market size of US$ 229.1 Million in the year 2033 and is projected at a CAGR of 4.17% during 2023-2033. This can be attributed to the emerging popularity…
Waldenstrom Macroglobulinemia Therapeutics Market Sluggish Growth Rate Foreseen …
The Waldenstrom Macroglobulinemia Therapeutics Market size is expected to grow at an annual average of CAGR 4% during the forecast period (2023-2029). Waldenstrom macroglobulinemia (WM) is a rare blood cell cancer characterized by the production of large amounts of an abnormal protein (called macroglobulin) by cancer cells. WM is a type of non-Hodgkin lymphoma (NHL) and is also known as lymphoplasmacytic lymphoma. WM is a low-grade B cell lymphoproliferative neoplasm…
Waldenstrom Macroglobulinemia Treatment Market Business Opportunities Forecast t …
According to Precision Business Insights (PBI), latest report, the waldenstrom macroglobulinemia treatment market size was valued at USD 163.7 million in 2022 and is expected to grow at a CAGR of 6.7% during the forecast period 2023 to 2029. The primary factors that drive the market are the growing prevalence of white blood cell lymphoma among geriatric people, rising in new treatment therapies, and the increasing demand for novel drugs…
Waldenstrom Macroglobulinemia Market Report- Statistical Analysis, Business Oppo …
The Waldenstrom Macroglobulinemia Market research report segments the market based on type, applications, end-users, and different geographies. Waldenstrom Macroglobulinemia Market helps new entrants/ stakeholders to understand the market trends and plan robust market strategies. Moreover, Waldenstrom Macroglobulinemia Market report also offers a covid-19 impact on the Waldenstrom Macroglobulinemia Market, enabling businesses to understand market drivers and restraints.
Get FREE PDF Sample of the Report @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5154352
Waldenstrom Macroglobulinemia Market provides an overview…
